系统综述与荟萃分析:溃疡性结肠炎患者升级至免疫抑制剂和生物制剂治疗后继续使用氨基水杨酸的高患病率与高费用
BACKGROUND: Aminosalicylates are the most frequently prescribed treatment for ulcerative colitis (UC). In the absence of empirical evidence, clinicians are uncertain whether to continue aminosalicylates in patients with UC after escalating therapy.…
要点
- 溃疡性结肠炎患者进入免疫抑制剂、生物制剂或口服小分子药物试验时,约80%继续使用氨基水杨酸。
- 合并使用氨基水杨酸的合并比例为80.7%(95%CI 75.5%-85.1%),异质性I²=95%。
核心结论
- 约80%的溃疡性结肠炎患者在接受免疫抑制剂、生物制剂或口服小分子药物临床试验时继续使用氨基水杨酸。
- 需要一项随机对照试验来指导升级治疗的患者继续使用与停用氨基水杨酸的获益与危害。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、Embase和CENTRAL从建库至2017年3月1日的安慰剂对照随机对照试验,纳入成人溃疡性结肠炎患者接受免疫抑制剂、生物制剂或口服小分子药物的试验。
- 共纳入32项试验,其中23项仅为诱导试验,9项为诱导和维持试验。
- 采用随机效应模型合并试验入组时合并使用氨基水杨酸的患者比例,并进行荟萃回归分析评估与氨基水杨酸使用相关的试验层面因素。
- 治疗费用使用加拿大五个省份2018年处方集数据估算。
主要发现
- 合并使用氨基水杨酸的合并比例为80.7%(95%CI 75.5%-85.1%),观察到相当大的异质性(I²=95%)。
- 在单变量荟萃回归中,氨基水杨酸使用与试验设计、研究场景、发表年份、疾病严重程度、疾病病程或药物类别均无关。
关键数值与推荐
- 合并使用氨基水杨酸的合并比例为80.7%(95%CI 75.5%-85.1%),异质性I²=95%。
- 单变量荟萃回归显示氨基水杨酸使用与试验设计、研究场景、发表年份、疾病严重程度、疾病病程或药物类别均无关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 观察到相当大的异质性(I²=95%)。
- 需要一项随机对照试验来指导升级治疗的患者继续使用与停用氨基水杨酸的获益与危害。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Aminosalicylates are the most frequently prescribed treatment for ulcerative colitis (UC). In the absence of empirical evidence, clinicians are uncertain whether to continue aminosalicylates in patients with UC after escalating therapy. AIMS: To quantify concomitant aminosalicylate use in UC randomised clinical trials (RCTs), identify factors associated with their use, and estimate treatment costs of concomitant aminosalicylate therapy. METHODS: MEDLINE, Embase, and CENTRAL were searched from inception to 1 March 2017 for placebo-controlled RCTs of immunosuppressants, biologics, or oral small molecules in adults with UC. The proportion of patients prescribed concomitant aminosalicylates at trial entry was pooled using a random-effects model. Meta-regression was performed to assess trial-level factors associated with aminosalicylate use. Treatment costs were estimated using 2018 formulary data from five Canadian provinces. RESULTS: Thirty-two trials were included (23 induction only, nine induction, and maintenance trials). The pooled proportion of patients co-prescribed aminosalicylates was 80.7% (95% CI 75.5%-85.1%), with considerable observed heterogeneity (I2 = 95%). In univariable meta-regression, aminosalicylate use was not associated with trial design, setting, year of publication, disease severity, disease duration, or drug class. The estimated direct annual treatment cost of concomitant aminosalicylates is ~$20 million for the Canadian UC population, assuming conservative estimates of UC prevalence, aminosalicylate use and dose, and the lowest cost formulation. CONCLUSIONS: Approximately 80% of UC patients entering clinical trials of immunosuppressants, biologics, or oral small molecules continue to use aminosalicylates. An RCT is needed to inform the benefits and harms of continuing vs stopping aminosalicylates in patients escalating therapy.
引用
- Ma C, Guizzetti L, Cipriano LE, et al. Systematic review with meta-analysis: high prevalence and cost of continued aminosalicylate use in patients with ulcerative colitis escalated to immunosuppressive and biological therapies. Aliment Pharmacol Ther. 2018. PMID: 30569460. doi:10.1111/apt.15090
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。